CD274 and neoplasm: ICIs have shown promising activity in gastro-oesophageal cancer (Table 1), with response rates in pre-treated patients ranging from 11 to 24%, depending on the combined positivity score (CPS; the ratio of cells (both tumour and immune) expressing PD-L1 relative to the number of viable tumour cells).17 The response rates appear constant regardless of line of therapy,17,27,28 which suggests that a distinct population of patients who will benefit exists.